ArticleCureus2025
Antisynthetase Syndrome With Cardiac Involvement: Role of Cardiac Magnetic Resonance Imaging in Its Diagnosis and Management.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present a case of newly diagnosed heart failure with reduced ejection fraction secondary to antisynthetase syndrome (ATS) in a 63-year-old female patient. The patient presented with symptoms and laboratory findings indicative of an ATS flare, which included inflammatory arthritis, muscular involvement, and exertional dyspnea. A systematic and structured diagnostic approach was undertaken, commencing with transthoracic echocardiography (TTE) to evaluate cardiac function and morphology. This was followed by ischemic assessment through coronary angiography to rule out ischemic heart disease, and subsequently, cardiac magnetic resonance imaging (CMR) based on findings from the TTE. The initial TTE revealed a newly reduced ejection fraction of 30-35%, a significant decline from previous normal echocardiograms. The ischemic evaluation identified mild, non-obstructive coronary artery disease, effectively excluding ischemic cardiomyopathy as a contributing factor. CMR was pursued due to concerns for myocarditis and provided further diagnostic clarity, revealing impaired left ventricular (LV) systolic function and near-transmural late gadolinium enhancement (LGE) in the inferolateral and anterolateral wall segments, along with subendocardial LGE in the inferoseptal wall segment. These findings were consistent with regional wall motion abnormalities observed on TTE. In response, the patient's baseline immunosuppressive therapy was optimized with the addition of mycophenolic acid. No additional etiologies were identified to account for the new LV dysfunction. Following optimization of immunosuppressive therapy and heart failure management, the patient exhibited significant clinical improvement, including stabilization of cardiac function and resolution of inflammatory markers. This case report adds to sparse literature describing ATS-induced myocarditis and helps highlight integration of advanced imaging modalities like CMR, which provides critical insights into myocardial tissue characterization and helps guide management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.